Hansoh Pharma’s Riz‑Rez Phase‑III Win: A Milestone for China’s Lung‑Cancer Market
HSPharm’s phase‑III win: Riz‑Rez boosts overall survival in advanced NSCLC, a breakthrough that could reshape China’s oncology market and lift investor confidence.
3 minutes to read